Although originally classified as anti-hyperglycemic drugs, SGLT2 inhibitors reduced the risk of HF hospitalization, CV death, and all-cause mortality in patients with HFrEF (84–86). This evidence concerns the gene SLC5A2 and hydrops fetalis.